Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release and the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling. Cynaropicrin has IC50 values of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin strongly inhibited TNF-alpha release from lipopolysaccharide-stimulated murine macrophage, RAW264.7 cells, and differentiated human macrophage, U937 cells. It also potently attenuated the accumulation of NO released from lipopolysaccharide- and interferon-gamma-stimulated RAW264.7 cells in a dose-dependent manner.
Molecular Weight | 346.37 |
Formula | C19H22O6 |
CAS Number | 35730-78-0 |
Solubility (25°C) | DMSO 50 mg/mL |
Storage | -20°C, protect from light, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related TNF Receptor Products |
---|
Chilob7/4
Chilob7/4 is a chimeric agonist anti-CD40 IgG1 antibody that can be used for tumor-related studies. |
VIB4920
VIB4920 is a fusion protein that binds to CD40L on activated T cells and blocks the interaction of CD40L with CD40-expressing B cells and other possible binding substrates. |
ABBV-428
ABBV-428 is a bispecific antibody targeting CD40/Mesothelin and can be used in studies related to solid tumors. |
TNF-α (31-45), human
TNF-α (31-45), human is a potent NF-kB pathway activator. |
LEESGGGLVQPGGSMK
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.